In the field of Alzheimer’s disease, no company has suffered more defeat than Lilly. However, this does not prevent the pharmaceutical giant from betting on Alzheimer’s disease assets again and signing a $2 billion deal. Eli Lilly’s core asset, developed in collaboration with AC Immune, is a drug code-named… Continue Reading Lilly will gamble on Alzheimer’s disease and collaborate to develop a preclinical Tau protein-targeted drug for $2 billion.
On November 30, Pfizer announced a settlement with AbbVie on a worldwide patent litigation against adalimumab biosimilars. Under the agreement, in the European market, Pfizer’s adalimumab biosimilars will be available for sale upon approval by the EMA. However, in the US market, Pfizer needs to market adalimumab biosimilars on… Continue Reading Pfizer and AbbVie reach a settlement, delaying the launch of Humira-like drugs in the US
Last year, the rumor that Pascal Soriot had to change to the CEO of Teva was very rampant, and the reasons for his departure were constant. Pascal Soriot himself declined to comment directly on the matter and later sent an internal memo to the staff, urging them to continue… Continue Reading Rumors: AstraZeneca will replace the CEO? Successor candidates may be generated internally
Since August 2017, the FDA has approved a total of four therapeutic drugs that are different from traditional small molecule drugs and macromolecular drugs. They are Novartis CAR-T drugs Kymriah (tisagenlecleucel-T) and Gilead (Kite). CAR-T drug Yescarta (axicabtagene ciloleucel), Spark gene therapy drug Luxturna (voretigene neparvovec-rzyl) and small interfering… Continue Reading The layout of global TOP10 pharmaceutical companies in the CAR-T field
On July 25, Gilead released its second quarter earnings report for 2018, achieving operating income of 5.648 billion US dollars. Although it still fell 21% compared with the same period of 2017, it is true that Gilead has continued to fall after several consecutive quarters of revenues. There are signs… Continue Reading Gilead 2018Q2 quarterly report: revenues stabilized and stabilized, CAR-T outstanding performance
“The reason why the medicine is expensive is because you bought the second medicine. The price of the first medicine is billions of dollars.” It is cheap to produce tablets and it is difficult to develop new drugs. This is every pharmaceutical circle. The basic logic that was instilled at… Continue Reading Gleevec’s cost and price
In early June, some media reported that Merck, the world’s oldest pharmaceutical company, will soon celebrate its 350th birthday. The most wanted gift is the Chinese market! A few days ago, this veteran pharmaceutical company found a new business partner – Ali Health. On June 20, Merck and Ali signed… Continue Reading In order to get a 350th birthday gift, old Merck found a “little fresh meat.”
On June 11th, Alexion and Complement Pharmaceuticals announced that they have reached a cooperation agreement to jointly develop the pre-clinical phase of the complement C6 inhibitor CP010 for the treatment of neurodegenerative diseases. Complement is a group of thermolabile proteins that exist on the surface of serum, tissue fluid and… Continue Reading Alexion and Complement Pharmaceutical Collaborate to Jointly Develop C6 Inhibitors
The data displayed by Mercury’s I-O star Keytruda on the ASCO 2018 is amazing, and almost everyone believes that Keytruda has no doubt seized the throne of lung immunotherapy. However, competitors do not seem to agree with this. In their view, the difference between their drug and Keytruda is very… Continue Reading What is the difference between the PD-1/PD-L1 drugs in Merck, BMS, and Roche?
Hookipa and Gilead will jointly develop therapies for the treatment of HIV and hepatitis B infection The two parties will jointly conduct research and Hookipa will produce Shamir Virus-based vectors for the clinical development of Gilead. This transaction expands the existing cooperation between Hookipa and Gilead – Gilead participated in… Continue Reading Promoting the cure for AIDS and hepatitis B virus, Gilead reached a research and development cooperation with Hookipa